Table 3.

Patient characteristics at baseline (n = 424)

	QCT group
	>=0 SD		<0 to −1 SD		<−1 to −2 SD		<−2 SD		Total
	n	%	n	%	n	%	n	%	n	%
Age at cancer treatment (years)
0–1	17	42.5	14	35.0	9	22.5	0	0	40	9.4
2–5	74	33.2	79	35.4	53	23.8	17	7.6	223	52.6
6–12	32	31.1	35	34.0	26	25.2	10	9.7	103	24.3
>=13	22	38.6	20	35.1	14	24.6	2	3.5	57	13.4
Age at BONEII enrollment (years)
9–12	27	27.6	36	36.7	25	25.5	10	10.2	98	23.1
13–18	57	34.1	54	32.3	43	25.7	13	7.8	167	39.4
19–30	50	37.6	49	36.8	28	21.1	6	4.5	133	31.4
31–40	11	42.3	9	34.6	6	23.1	0	0	26	6.1
Sex
Female	85	41.3	71	34.5	40	19.4	10	4.9	206	48.6
Male	60	27.5	77	35.3	62	28.4	19	8.7	218	51.4
Race
White	111	30.4	137	37.5	93	25.5	24	6.6	365	86.1
Black	32	60.4	9	17.0	7	13.2	5	9.4	53	12.5
Other	2	33.3	2	33.3	2	33.3	0	0	6	1.4
Body mass index
Below Normal (< 19	15	23.1	26	40.0	18	27.7	6	9.2	65	15.3
Normal (≥ 19 but < 25)	53	29.8	64	36.0	47	26.4	14	7.9	178	42.0
Overweight (≥ 25 but < 30)	31	33.3	35	37.6	21	22.6	6	6.5	93	21.9
Obese (≥ 30)	46	56.8	23	29.1	16	20.3	3	3.8	79	20.7
Menarchal status
Menstruating	76	44.4	59	34.5	31	18.1	5	2.9	171	40.3
Not menstruating	7	22.6	12	38.7	7	22.6	5	16.1	31	7.3
Not applicable – male	62	27.9	77	34.7	64	28.8	19	8.6	222	52.4
Unknown	2	22.2	4	44.4	2	22.2	1	11.1	9	2.1
Cranial irradiation
None	81	29.6	101	36.9	70	25.5	22	8.0	274	64.6
1800 cGy	54	47.0	37	32.2	21	18.3	3	2.6	115	27.1
>2400 cGy	10	28.6	10	28.6	11	31.4	4	11.4	35	8.3
6-Mercaptopurine
<=17338 mg (median)	68	33.0	76	36.9	48	23.3	14	6.8	206	48.6
>17338 mg	77	35.3	72	33.0	54	24.8	15	6.9	218	51.4
Cyclophosphamide
<=5868 mg (median)	83	34.6	80	33.3	60	25.0	17	7.1	240	56.6
>5868 mg	62	33.7	68	37.0	42	22.8	12	6.5	184	43.4
Methotrexate
<=8406 mg (median)	69	33.0	70	33.5	55	26.3	15	7.2	209	49.3
>8406 mg	76	35.3	78	36.3	47	21.9	14	6.5	215	50.7
Prednisone
<=3735 mg (median)	79	36.2	70	32.1	53	24.3	16	7.3	218	51.4
>3735 mg	66	32.0	78	37.9	49	23.8	13	6.3	206	48.6
Total	145	34.2	148	34.9	102	24.1	29	6.8	424	100